TCGA-OR-A5JT-01
Adrenocortical Carcinoma · Adrenocortical Carcinoma · Adrenocortical Carcinoma, Usual Type
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
- cancer_type
- Adrenocortical Carcinoma
- cancer_type_detailed
- Adrenocortical Carcinoma
- subtype
- Adrenocortical Carcinoma, Usual Type
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.300
- OXIDATIVE_PHOSPHORYLATION+0.299
- FATTY_ACID_METABOLISM+0.280
- INTERFERON_ALPHA_RESPONSE+0.227
- MITOTIC_SPINDLE+0.206
- INTERFERON_GAMMA_RESPONSE+0.164
- ADIPOGENESIS+0.161
- GLYCOLYSIS+0.118
- APOPTOSIS+0.109
- ANGIOGENESIS+0.108
Top 10 suppressed
- MYC_TARGETS_V2-0.372
- CHOLESTEROL_HOMEOSTASIS-0.310
- MYC_TARGETS_V1-0.282
- DNA_REPAIR-0.217
- PANCREAS_BETA_CELLS-0.200
- TGF_BETA_SIGNALING-0.198
- APICAL_SURFACE-0.175
- TNFA_SIGNALING_VIA_NFKB-0.165
- WNT_BETA_CATENIN_SIGNALING-0.153
- KRAS_SIGNALING_DN-0.128
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-OR-A5JR-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.660 |
| 2 | TCGA-A2-A0YC-01A-11R-A109-07 | — | B | 0.600 |
| 3 | TCGA-BL-A0C8-01A-11R-A277-07 | — | — | 0.557 |
| 4 | SRR1797274 | — | cohortSC | 0.547 |
| 5 | TCGA-E9-A1RD-01A-11R-A157-07 | — | B | 0.542 |
| 6 | MNG398 | — | — | 0.522 |
| 7 | TCGA-D8-A1XU-01A-11R-A14M-07 | — | A | 0.516 |
| 8 | 399e5b76-1d8d-4db9-a186-ffdc2f6e0884 | — | — | 0.515 |
| 9 | BS_52DAPP1Y | low-grade glioma | — | 0.514 |
| 10 | SJEPD031233_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.511 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 23 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.300 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.299 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.227 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.206 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.164 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.161 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.118 | Inavolisib | — uncovered |
| APOPTOSIS | 0.109 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.108 | Remibrutinib | — uncovered |
| HEME_METABOLISM | 0.103 | Temsirolimus | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.102 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.099 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.095 | Inavolisib | — uncovered |
| MYOGENESIS | 0.083 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.066 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.065 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.062 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.054 | Inavolisib | — uncovered |
| COMPLEMENT | 0.025 | Inavolisib | — uncovered |